Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Peter Nihill"'
Autor:
Kelly Hosking, Paula Binks, Teresa De Santis, Phillip Merrdi Wilson, George Garambaka Gurruwiwi, Sarah Mariyalawuy Bukulatjpi, Emily Vintour-Cesar, Melita McKinnon, Peter Nihill, Tammy-Allyn Fernandes, Belinda Greenwood-Smith, Robert Batey, Cheryl Ross, Steven Y.C. Tong, Geoffrey Stewart, Catherine Marshall, Catherine Gargan, Prashanti Manchikanti, Karen Fuller, Jaclyn Tate-Baker, Sami Stewart, Benjamin Cowie, Nicole Allard, Jennifer H. MacLachlan, Ashleigh Qama, David Boettiger, Joshua S. Davis, Christine Connors, Jane Davies
Publikováno v:
The Lancet Regional Health. Western Pacific, Vol 48, Iss , Pp 101116- (2024)
Summary: Background: The Northern Territory (NT) has the highest prevalence of chronic hepatitis B (CHB) in Australia. The Hep B PAST program aims to improve health outcomes for people living with CHB. Methods: This mixed methods study involves First
Externí odkaz:
https://doaj.org/article/e640f03b03b949ae9476e4e66d463b6c
Autor:
Kelly Hosking, Geoffrey Stewart, Mikaela Mobsby, Steven Skov, Yuejen Zhao, Jiunn-Yih Su, Steven Tong, Peter Nihill, Joshua Davis, Christine Connors, Jane Davies
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0232207 (2020)
BackgroundChronic hepatitis B (CHB) is endemic in the Aboriginal population of Australia's Northern Territory (NT). However, many people's hepatitis B virus (HBV) status remains unknown.Objective1. To maximise the utility of existing HBV test and vac
Externí odkaz:
https://doaj.org/article/73415819fcc14acab747741c06d6b0f4
Autor:
Christine Connors, Jiunn-Yih Su, Geoffrey Stewart, Yuejen Zhao, Kelly Hosking, Peter Nihill, Joshua S. Davis, Jane Davies, Steven Y. C. Tong, Steven Skov, Mikaela Mobsby
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 4, p e0232207 (2020)
PLoS ONE, Vol 15, Iss 4, p e0232207 (2020)
BackgroundChronic hepatitis B (CHB) is endemic in the Aboriginal population of Australia's Northern Territory (NT). However, many people's hepatitis B virus (HBV) status remains unknown.Objective1. To maximise the utility of existing HBV test and vac